Search

Deprivation of glucose and lactate provides an effective pathway to terminate the nutrients supplement for tumor growth. In this work, biomimetic nanozymes called m@BGLC are constructed for catalytic tumor inhibition through nutrients deprivation and oxidative damage induction. Concretely, the catalytic enzymes of glucose oxidase (GOx), lactate oxidase (LOx) and chloroperoxidase (CPO) are precrosslinked with bovine serum albumin (BSA) to construct nanozymes, which are then biomimetic functionalized with cancer cell membrane to prepare m@BGLC. Benefiting from the biomimetic camouflage with homologous cell membrane, m@BGLC inherit homotypic binding and immune escape abilities, facilitating the tumor targeting accumulation and preferable cell internalization for improved drug delivery efficiency. Subsequently, under the cascade catalysis of nanozymes, m@BGLC consume glucose and lactate for tumor starvation therapy through nutrients deprivation, and meanwhile, the resulting hyprochloric acid (HClO) causes an oxidative damage of cells to synergistically inhibit tumor growth. In vitroand in vivofindings demonstrate a robust tumor eradication effect of m@BGLC without obvious adverse reactions viathe targeted combination therapy. Such cascade catalytic nanomedicine may inspire the development of sophisticated strategies for tumor combination therapy under unfavorable tumor microenvironments.

Oxidative therapies receive a limited antitumor efficiency due to the insufficient reactive oxygen species (ROS) levels at focal sites and the evolvement of antioxidant defense systems. Herein, we develop an albumin-based nanomedicine to co-deliver chlorin e6 (Ce6) and COH-SR4 (CS), which can simultaneously enhance the yield and lethality of intracellular ROS for amplified photodynamic therapy (PDT). In which, CS acts as both an activator of AMP-activated protein kinase (AMPK) and an inhibitor of glutathione S-transferases (GSTs). Benefiting from it, the prepared HSA-Ce6@COH-SR4 (HCCS) enables positive feedback uptake by promoting AMPK phosphorylation, leading to rapid and extensive tumor accumulation of drugs. As a result, HCCS obviously increases the ROS production to elevate intracellular oxidative stress. Furthermore, HCCS can inhibit GSTs to disturb the antioxidant defense system of tumor cells, intensifying the oxidative damage of ROS. Ultimately, the PDT of HCCS is significantly strengthened by improving the ROS yield and lethality, which greatly declines the proliferation of breast cancer in vivo. This study may open a window in the development of drug co-delivery system for enhanced oxidative therapy of tumors.